Oxford Biomedica celebrates agreements with three US companies
Gene and cell therapy group, Oxford Biomedica, has announced that its subsidiary Oxford Biomedica Solutions has signed agreements with three new U.S. based biotechnology companies.
This is in addition to the new AAV, Adeno-Associated Virus (AAV), customer announced in September 2022.
Oxford Biomedica Solutions will provide its full platform offering to support the new partners' pre-clinical gene therapy programmes, which cover a range of indications.
READ MORE: Oxford Biomedica to sell and leaseback its facility for £60 million
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: "We are making considerable progress towards becoming a global viral vector leader across all key vector types, with this momentum in Oxford Biomedica Solutions adding to the strength and depth of our UK-based operations.
"AAV is a significant, high growth market, and the cadence of new business wins further reinforces our confidence in the potential of our AAV platform."
PICTURE: Oxford Biomedia
